Radiation and immune drug combo aims to boost breast cancer treatment before chemo

NCT ID NCT07188246

Recruiting now Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 27 times

Summary

This study is for people with stage 2 or 3 breast cancer. It tests whether giving a special type of radiation (SBRT) and an immunotherapy drug (pembrolizumab) directly into the tumor before standard chemotherapy can help shrink the cancer more effectively. The goal is to see if this approach leads to a complete disappearance of cancer in the breast tissue after all treatments. About 40 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

St. Joseph's Health Care London
NOT_YET_RECRUITING

London, Ontario, N6A 4V2, Canada
St. Joseph's Health Care London
RECRUITING

London, Ontario, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER BREAST CANCER INVASIVE BREAST CANCER STAGE II BREAST CANCER STAGE III BREAST CANCER TRIPLE NEGATIVE